Medical device company Globus Medical (NYSE:GMED) in Q1 CY2025, with sales falling 1.4% year on year to $598.1 million. On ...

On Tuesday, May 27, an analyst from BTIG downgraded Globus Medical Inc. (NYSE:GMED) from Buy to Neutral, citing concerns about its Spine business. The analyst did not assign a price target following ...

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $77.5, a high estimate of $82.00, and a low estimate of $68.00. A negative shift in sentiment is ...

Globus Medical, Inc. GMED continues to benefit from the robust demand for its Musculoskeletal Solutions products. Following the NuVasive merger, the combined company has formed a global ...

BTIG analysts have downgraded Globus Medical from "Buy" to "Neutral" amid fears surrounding the company's Spine business.

Globus Medical GMED has entered into a definitive agreement to acquire Nevro Corp. NVRO in an all-cash transaction valued at approximately $250 million. Under the terms of the agreement ...

Globus Medical AUDUBON, Pa., April 17, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal technology company, will announce its financial results for the first ...

Globus Medical, Inc. (GMED) key stats comparison: compare with other stocks by metrics: valuation, growth, profitability, momentum, EPS revisions, dividends, ratings. Skip to content Home page ...

Pennsylvania-based Globus Medical, Inc. company is primarily focused on products for knee and hip procedures, as well as robotic and imaging systems. However, its main business is providing a wide ...

Globus Medical AUDUBON, Pa., April 03, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal technology company, today announced the completion of its previously ...